Superior Overall Survival in First Relapse or Refractory
FLT3m+ AML vs Salvage Chemotherapy1

PRIMARY ENDPOINT: OVERALL SURVIVAL (INTENTION-TO-TREATMENT SET)1,2


Graph of overall survival in the ADMIRAL trial. 36% reduced risk of death with XOSPATA vs salvage chemotherapy. Graph of overall survival in the ADMIRAL trial. 36% reduced risk of death with XOSPATA vs salvage chemotherapy.
  • Median overall survival was based on Kaplan-Meier estimates2
9.3 months Median Overall Survival with XOSPATA

Median OS With XOSPATA

(95% CI: 7.7, 10.7)

5.6 months Median Overall Survival with salvage chemotherapy

Median OS With Salvage Chemotherapy

(95% CI: 4.7, 7.3)

HR=0.64 (95% Cl: 0.49, 0.83); P=0.0004

37.1%

estimated with XOSPATA
(95% CI: 30.7, 43.6)

16.7%

estimated with salvage chemotherapy
(95% CI: 9.9, 25.0)

  • Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula2

In the exploratory subgroup analyses that evaluated survival according to whether patients were preselected for high-intensity or low-intensity chemotherapy1:

34%

reduced risk of death with XOSPATA vs high-intensity chemotherapy (HR=0.66; 95% CI: 0.47, 0.93)

44%

reduced risk of death with XOSPATA vs low-intensity chemotherapy (HR=0.56; 95% CI: 0.38, 0.84)